What is more, major international guidelines all highly recommend the use (or combined use) of SGLT2 inhibitors in patients with T2DM with comorbid CVDs (or high risk of CVDs) and/or CKD, with the ESC/EASD guidelines (7) recommending them over metformin in newly diagnosed patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.